• Chart
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs
    1. Home
    2. Stocks
    3. Supriya Share Price

    Supriya Lifescience Share PriceSupriya Lifescience

    Small Cap 7.2k Result
    ₹272.1
    -3.5 (-1.27%)
    As on 11 December, 2023 | 01:57 BSE: 543434 NSE: SUPRIYAISIN: INE07RO01027

    Supriya Lifescience Performance

    Day Range

    • Low 270.50
    • High 281.40
    ₹ 272.1

    52 Week Range

    • Low 170.15
    • High 310.60
    ₹ 272.1
    • Open Price276.90
    • Previous Close275.60
    • Volume281551

    Start SIP in Supriya Lifescience

    Start SIP

    Supriya Lifescience Share Price

    • Over 1 Month 11.47%
    • Over 3 Month -10.8%
    • Over 6 Month 6.14%
    • Over 1 Year 11.22%

    Supriya Lifescience Key Statistics

    P/E Ratio 21.9
    PEG Ratio -1
    Market Cap Cr 2,190
    Price to Book Ratio 3.1
    EPS 11.2
    Dividend 0.2
    Relative Strength Index 54.54
    Money Flow Index 77.23
    MACD Signal 5.63
    Average True Range 9.75

    Supriya Lifescience Investment Rating

    • Master Rating:

    • Supriya Lifescience has an operating revenue of Rs. 519.53 Cr. on a trailing 12-month basis. An annual revenue de-growth of -12% needs improvement, Pre-tax margin of 27% is great, ROE of 12% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 10% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It is currently FORMING a base in its weekly chart and is trading around 7% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 86 which is a GOOD score indicating consistency in earnings, a RS Rating of 33 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 154 indicates it belongs to a poor industry group of Medical-Supplies and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Supriya Lifescience Financials
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 140132142105112101181
    Operating Expenses Qtr Cr 1088887916170106
    Operating Profit Qtr Cr 32445514523175
    Depreciation Qtr Cr 4433333
    Interest Qtr Cr 01112411
    Tax Qtr Cr 61415311529
    Net Profit Qtr Cr 24293810172546
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 470538
    Operating Expenses Annual Cr 332316
    Operating Profit Annual in Cr 129214
    Depreciation Cr 1210
    Interest Annual Cr 34
    Tax Annual Cr 3455
    Net Profit Annual Cr 90152
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 6649
    Cash from Investing Activity Annual Cr -133-60
    Cash from Financing Annual Activity Cr -3150
    Net Cash Flow Annual Cr -70139
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 699616
    Fixed Assets Annual Cr 329233
    Total Non Current Assets Annual Cr 355237
    Total Current Assets Annual Cr 465498
    Total Assets Annual Cr 820735
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 8776
    ROE Annual % 1325
    ROCE Annual % 1733
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 3042
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr
    Operating Expenses Qtr Cr
    Operating Profit Qtr Cr
    Depreciation Qtr Cr
    Interest Qtr Cr
    Tax Qtr Cr
    Net Profit Qtr Cr
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr
    Operating Expenses Annual Cr
    Operating Profit Annual in Cr
    Depreciation Cr
    Interest Annual Cr
    Tax Annual Cr
    Net Profit Annual Cr
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr
    Cash from Investing Activity Annual Cr
    Cash from Financing Annual Activity Cr
    Net Cash Flow Annual Cr
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr
    Fixed Assets Annual Cr
    Total Non Current Assets Annual Cr
    Total Current Assets Annual Cr
    Total Assets Annual Cr
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs
    ROE Annual %
    ROCE Annual %
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin %
    Invest in Supriya Lifescience

    Supriya Lifescience Technicals

    EMA & SMA

    Current Price
    ₹272.1
    -3.5 (-1.27%)
    pointer
    • Bullish Moving Average
    • ___
    • 11
    • Bearish Moving Average
    • ___
    • 5
    • 20 Day
    • ₹268.97
    • 50 Day
    • ₹263.95
    • 100 Day
    • ₹260.85
    • 200 Day
    • ₹262.31
    • 20 Day
    • ₹265.14
    • 50 Day
    • ₹259.74
    • 100 Day
    • ₹265.23
    • 200 Day
    • ₹245.33

    Supriya Lifescience Resistance and Support

    PIVOT
    ₹274.67
    Resistance
    First Resistance 278.83
    Second Resistance 285.57
    Third Resistance 289.73
    RSI 54.54
    MFI 77.23
    MACD Single Line 5.63
    MACD 6.65
    Support
    First Resistance 267.93
    Second Resistance 263.77
    Third Resistance 257.03

    Supriya Lifescience Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 294,340 12,995,111 44.15
    Week 274,784 13,401,235 48.77
    1 Month 575,661 22,658,004 39.36
    6 Month 371,925 15,661,756 42.11

    Supriya Lifescience Result Highlights

    Supriya Lifescience Synopsis

    NSE-Medical-Supplies

    Supriya Lifescience is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 460.94 Cr. and Equity Capital is Rs. 16.10 Cr. for the Year ended 31/03/2023. Supriya Lifescience Ltd. is a Public Limited Listed company incorporated on 26/03/2008 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L51900MH2008PLC180452 and registration number is 180452.
    Market Cap 2,190
    Sales 520
    Shares in Float 2.58
    No of funds 22
    Yield 0.22
    Book Value 3.13
    U/D Vol ratio 0.9
    LTDebt / Equity
    Alpha 0.04
    Beta 0.96

    Supriya Lifescience

    Owner NameSep-23Jun-23Mar-23Dec-22
    Promoters 68.3%68.3%68.28%68.24%
    Mutual Funds 1.74%2.14%2.38%2.38%
    Insurance Companies 3.89%3.86%3.73%3.85%
    Foreign Portfolio Investors 5.35%5.73%5.66%6.24%
    Individual Investors 16.1%15.4%15.55%15.07%
    Others 4.62%4.57%4.4%4.22%

    Supriya Lifescience Management

    Name Designation
    Mr. Satish Waman Wagh Chairman & Managing Director
    Ms. Smita Satish Wagh Whole Time Director
    Ms. Saloni Satish Wagh Whole Time Director
    Ms. Shivani Satish Wagh Whole Time Director
    Mr. Balasahab Gulabrao Sawant Whole Time Director
    Mr. Kedar Shankar Karmarkar Independent Director
    Mr. Bhairav Manojbhai Chokshi Independent Director
    Mr. Dileep Kumar Jain Independent Director
    Mr. Dinesh Navnitlal Modi Independent Director
    Ms. Neelam Yashpal Arora Independent Director

    Supriya Lifescience Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Supriya Lifescience Corporate Action

    Date Purpose Remarks
    2023-11-07 Quarterly Results
    2023-08-03 Quarterly Results
    2023-05-26 Audited Results & Final Dividend
    2023-02-14 Quarterly Results
    2022-11-10 Quarterly Results

    Supriya Lifescience MF Shareholding

    Name Amount(cr)
    Nippon India Small Cap Fund - Growth 41,019
    Motilal Oswal Nifty Microcap 250 Index Fund Regular Growth 461
    Groww Nifty Total Market Index Fund Regular Growth 32
    Motilal Oswal S&P BSE Healthcare ETF 8

    Supriya Lifescience FAQs

    What is Share Price of Supriya Lifescience ?

    Supriya Lifescience share price is ₹272 As on 11 December, 2023 | 01:43

    What is the Market Cap of Supriya Lifescience ?

    The Market Cap of Supriya Lifescience is ₹2189.9 Cr As on 11 December, 2023 | 01:43

    What is the P/E ratio of Supriya Lifescience ?

    The P/E ratio of Supriya Lifescience is 21.9 As on 11 December, 2023 | 01:43

    What is the PB ratio of Supriya Lifescience ?

    The PB ratio of Supriya Lifescience is 3.1 As on 11 December, 2023 | 01:43

    Q2FY23

    More Information

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI REGN No.: ARN-104096 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support desk helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
    ©2023, 5Paisa Capital Ltd. All Rights Reserved.
    We are ISO 27001:2013 Certified.